A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation
Version of Record online: 9 JUL 2003
Journal of Internal Medicine
Volume 254, Issue 2, pages 184–192, August 2003
How to Cite
Tønnesen, P., Tonstad, S., Hjalmarson, A., Lebargy, F., Van Spiegel, P. I., Hider, A., Sweet, R. and Townsend, J. (2003), A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. Journal of Internal Medicine, 254: 184–192. doi: 10.1046/j.1365-2796.2003.01185.x
- Issue online: 9 JUL 2003
- Version of Record online: 9 JUL 2003
- Received 15 November 2002; revision received 12 March 2003; accepted 8 April 2003.
- bupropion sustained release;
- randomized controlled trials;
- smoking cessation;
- weight gain;
- withdrawal symptoms
Abstract. Tønnesen P, Tonstad S, Hjalmarson A, Lebargy F, van Spiegel PI, Hider A, Sweet R, Townsend J (Gentofte University Hospital, Gentofte, Denmark; Clinic for Preventive Medicine, Ullevål University Hospital, Oslo, Norway; Smoking Cessation Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden; Hospital Maison Blanche, Reims Cedex, France; Slotervaart Hospital, Amsterdam, The Netherlands; and GlaxoSmithKline Research and Development, Greenford, Middlesex, UK). A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003; 254: 184–192.
Background. Bupropion sustained release (bupropion SR) has been shown to increase smoking cessation success rates in the US studies.
Objective. To determine whether bupropion SR, in combination with counselling, is effective for smoking cessation in a multi-country study.
Methods. This randomized, double-blind, placebo-controlled trial enrolled 707 smokers. A total of 527 received bupropion SR 300 mg daily for 7 weeks and 180 received placebo. A total of 11 clinic visits and 10 telephone contacts were scheduled, during the course of 1 year. Seven-week and 12-month abstinence rates were the study outcomes.
Results. Both continuous and weekly point prevalence smoking abstinence rates were significantly higher in the bupropion SR group compared with placebo. The continuous abstinence rate from weeks 4 to 7 was 46% in the bupropion SR group compared with 23% in the placebo group [odds ratio (OR) = 2.82; 95% confidence interval (CI) 1.89–4.28; P < 0.001). At month 12, the continuous abstinence rates were 21% for the bupropion SR group and 11% for the placebo group (OR = 2.19; 95% CI 1.29–3.86, P = 0.002). For most nicotine-withdrawal symptoms small changes were measured. Adverse events were higher for the bupropion SR group compared with placebo (insomnia 24% vs. 15%; dry mouth 13% vs. 5%).
Conclusion. Bupropion SR in combination with counselling increased the abstinence rate compared with placebo, and was well tolerated.